Navigation Links
U of M begins nation's first clinical trial using T-reg cells from cord blood in leukemia treatment
Date:9/5/2007

University of Minnesota researchers have initiated a ground breaking clinical trial to determine the optimal dose and safety of T regulatory cells (T-regs) to decrease the risk of immune reactions common in patients undergoing blood and marrow transplantation.

Ultimately, the researchers hope the experimental cellular therapy will improve overall survival rates for blood cancer patients as well as offer a potential new paradigm for treating autoimmune diseases.

Toward our quest of making transplants even safer for adults and children with leukemia, lymphoma, multiple myeloma, and other blood and marrow disorders, we are exploring the possibility of using T-regs to enhance the rate of blood and marrow recovery and reduce the risks of graft-versus-host disease, a complication that affects more than 60 percent of patients, said Claudio Brunstein, M.D., principal investigator of the study.

T-regs are a type of lymphocyte, or white blood cell that normally regulates the bodys immune responses. In the case of transplant, donor T-regs may suppress the recipients immune system so that the healthy donors blood-forming stem cells and immune cells can grow, helping ward off life-threatening graft-versus-host-disease (GVHD). GVHD occurs when the immune cells within the donated cells attack the body of the transplant recipient. GVHD causes one-third of deaths after transplant.

Researchers have proven in animal models that infusing T-regs after transplant increases the chance of blood and marrow recovery and decreases the risk of GVHD.

Once we identified that T-regs were highly effective in mouse models, we then spent three years finding ways to make this therapy valuable for transplant patients and potentially useful for patients with autoimmune diseases, said Bruce Blazar, M.D., director of the Center for Translational Medicine at the University.

The T-regs in this study are isolated from umbilical cord blood (blood collected from the placenta or
'/>"/>

Contact: Molly Portz
mportz@umn.edu
612-625-2640
University of Minnesota
Source:Eurekalert

1

GOOD

Page: 1 2

Related biology news :

1. International trial of two microbicides begins
2. NIAID begins clinical trial of West Nile virus vaccine
3. EuroVacc 02 HIV Vaccine Trial Begins
4. Wyoming cloud seeding experiment begins this month
5. Cancer scientists create human leukemia process to map how disease begins, progresses
6. Parents need to be educated about HPV vaccinations for daughters
7. Simple idea to dramatically improve dengue vaccinations
8. Novel therapy combinations gain ground in treating hepatitis
9. New study suggests promising drug combinations for sleeping sickness
10. Failure to meet United Nations sanitation target could affect millions of the worlds poorest
11. Effect on breast tumors of DNA alternations in 3 genes described
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...hnology (NIST) has developed Standard Reference Ma...k medicine and now increasingly used in herbal wei...erials to develop and test analytical methods for ...s for quality assurance of their measurements. The...address the use of bitter orange for health purpos...
(Date:5/16/2008)...rest Research presents the preliminary findings of...ape-scale experiments on how forest management aff...acks Mountain Interdisciplinary Research team incl...y, Oregon State University, U.C. Riverside, Univer...scientists collaborating in research on large-scal...
(Date:5/15/2008)...nearly 150 years ago, bird beaks are exquisitely a...IT mathematicians and engineers has now explained ...eaks to defy gravity and transport food into their...ern North America, takes advantage of surface inte...opel bits of food from the tip of its long beak to...
(Date:5/15/2008)... bacteria stick to surfaces depends partly on how ...ed ultrathin films made of polymers that could be ...ontrol microbe accumulation. , The inexpensive, ...er of protection for the health care industry by h...nfections, which take the lives of 100,000 people ...
Breaking Biology News(10 mins):Bitter orange SRMs: Tools for product analysis/quality 2Pioneering landscape-scale research releases first findings 2MIT solves gravity-defying bird beak mystery 2MIT solves gravity-defying bird beak mystery 3MIT crafts bacteria-resistant films 2MIT crafts bacteria-resistant films 3Pennsylvania Trauma Center Accreditation Status 3645 1Pennsylvania Trauma Center Accreditation Status 3645 2Facet Solutions AFRS 28TM 29 Implant Demonstrates Positive Clinical Results After One Year Follow Up 3643 1Facet Solutions AFRS 28TM 29 Implant Demonstrates Positive Clinical Results After One Year Follow Up 3643 2Pharmacopeia Acquires Selective Androgen Receptor Modulator 28SARM 29 Program from Bristol Myers Squibb 3641 1Pharmacopeia Acquires Selective Androgen Receptor Modulator 28SARM 29 Program from Bristol Myers Squibb 3641 2Pharmacopeia Acquires Selective Androgen Receptor Modulator 28SARM 29 Program from Bristol Myers Squibb 3641 3Pharmacopeia Acquires Selective Androgen Receptor Modulator 28SARM 29 Program from Bristol Myers Squibb 3641 4Pharmacopeia Acquires Selective Androgen Receptor Modulator 28SARM 29 Program from Bristol Myers Squibb 3641 5Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1 2007 1251 1Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1 2007 1251 2
... Researchers at Oregon Health & Science Univer...occurring brain substance, can relieve the doldrum...ective disorder, or SAD. The study is publishing o... Academy of Science. , The study was led by Alfred...pioneer in the study of circadian (24-hour) rhythm...
... An engineered virus tracks down and infects the m...n kills tumor cells by forcing them to devour them...D. Anderson Cancer Center report this week in the ...dified adenovirus homed in on malignant glioma cel... among the cancer cells -- a process called autoph...
... One of the body,s basic survival mechanisms is th...to the alertness needed for seeking food. That sam...al, as exemplified by the long and honored custom ... little about how the basic energy molecule, gluco...lated behaviors. , Now, in an article in the June ...
... Parasitic plants do not haphazardly flail about l...duced by other plants and identify potential hosts...tate chemical ecologists. , "We are interested in ...looked at plant insect interactions," says Dr. Con...ogy. "It was surprising to see how little was ava...
Other Biology News:Melatonin improves mood in winter depression 2Targeted virus compels cancer cells to eat themselves 2Targeted virus compels cancer cells to eat themselves 3New mechanism explains glucose effect on wakefulness 2New mechanism explains glucose effect on wakefulness 3Parasitic plants sniff out hosts 2Parasitic plants sniff out hosts 3
(Date:5/16/2008)...onsors Program to Recognize Exemplary Work ...IA, May 16 /- CURE magazine announced...y Healer Award for Oncology Nursing,during a recep...Annual,Congress. Ortho Biotech Products, L. P. spo... demonstrate unwavering dedication, compassion and...
(Date:5/16/2008).../- Senesco,Technologies, In...y reported,financial results for the three months ...th period ended March 31, 2008 was $2.0,million, o...8 million, or,$0.05 per share, for the three month... loss was primarily the result of an increase of $...
(Date:5/16/2008)...FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NA...ing interim,results of a Phase II study of intrave...tic to the lung is available on the American Socie...www.asco.org and on the Oncolytics,website at ht...ntitled "A Phase II,Study of Intravenous REOLYSIN ...
(Date:5/16/2008)... /- Arpida Ltd.,(SWX: ARPN)...istration,(FDA) has accepted for review the New Dr...he treatment of complicated Skin and Skin,Structur...ion of the NDA to,the agency in March 2008. FDA ha...prim NDA and has established the Prescription Drug...
Breaking Biology Technology:CURE Magazine Announces Winner of 2008 Extraordinary Healer Award 2Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 2Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 3Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 4Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 5Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 6Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 7Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 8Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting 2Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 2Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 3
...are has released a new medical imaging product fo...ance the image reading capabilities of radiologist...ct, marketed as Merge Mammo(TM) version 7.0, will ...images on devices ranging from ultrasound to digit...sition device is used to secure the images. The co...
... in a series of articles on developing start-up co.... The most recent article focused on the tax law i...rs. In this article, the authors address unemploym... unemployment insurance statute has its own test f...ough this test is similar in many respects to the ...
...se more venture capital for clinical trials, ZySt...g at the annual InvestMidwest venture capital for...hich also presented at the 2006 forum, would like ...cipation of Phase I clinical trials that are set t... the Technology Innovation Center at Milwaukee Co...
...ng with U.S. Health and Human Services Secretary...healthcare organizations pledged to support health...interoperability standards in the health informati... , ,The pledge came as part of an effort to suppo...care quality, information reporting, and cost-effe...
Other Biology Technology:Early Stage, Step 8: Misclassifying workers brings risk 2Early Stage, Step 8: Misclassifying workers brings risk 3Early Stage, Step 8: Misclassifying workers brings risk 4Early Stage, Step 8: Misclassifying workers brings risk 5ZyStor seeks to raise $15M for clinical trials 2ZyStor seeks to raise $15M for clinical trials 3Wisconsin firms pledge to support healthcare IT standards 2
WNV Core Antibody
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only
Rad51, N-terminal
Phospho-mu-Opioid Receptor (Ser375) Antibody
Biology Products: